Additional definitive proxy soliciting materials and Rule 14(a)(12) material




Washington, D.C. 20549


Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant x Filed by a party other than the Registrant ¨

Check the appropriate box:

¨ Preliminary proxy statement
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ Definitive proxy statement
x Definitive additional materials
¨ Soliciting material pursuant to §240.14a-12


(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.
¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

Title of each class of securities to which transaction applies:


Aggregate number of securities to which transaction applies:


Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it is determined):


Proposed maximum aggregate value of transaction:


Total fee paid:

¨ Fee paid previously with preliminary materials.
¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Amount previously paid:


Form, schedule or registration statement no.:


Filing party:


Date filed:



7 Hamilton Landing

Suite 100

Novato, CA 94949

(415) 408-6200




July 21, 2014

This proxy statement supplement (this “Supplement”) supplements the definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission by Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), on June 17, 2014 and made available to the Company’s stockholders in connection with the solicitation of proxies by the Company’s Board of Directors for the 2014 annual meeting of stockholders to be held at 8:00 a.m., local time, on July 29, 2014 at the Company’s corporate offices at 7 Hamilton Landing, Suite 100, Novato, California 94949, or at any adjournments or postponements thereof.

Only holders of record of shares of the Company’s common stock at the close of business on June 2, 2014 are entitled to notice of, and to vote at, the annual meeting.

The purpose of this Supplement is to update Timothy P. Walbert’s biography included in Proposal No. 1 to provide additional information regarding Mr. Walbert’s outside board memberships. Mr. Walbert is one of the Company’s current directors and is a nominee for director under Proposal No. 1. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply. This Supplement should be read in conjunction with the Proxy Statement.

Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting

to Be Held on July 29, 2014.

This Supplement, the Proxy Statement and Annual Report to Security Holders are available at or you may access these materials on the Company’s website at .

Mr. Walbert’s biography included in Proposal No. 1 is replaced in its entirety with the following.

Timothy P. Walbert. Mr. Walbert has served as a director of the Company since April 2011. He is currently the Chairman, President and Chief Executive Officer of Horizon Pharma, Inc., a publicly


traded biopharmaceutical company focused on developing and commercializing innovative medicines in arthritis, pain and inflammatory diseases. Prior to his time at Horizon Pharma, Mr. Walbert served as President, Chief Executive Officer and a director of IDM Pharma, Inc., a publicly traded oncology-focused biotechnology company, which was acquired by Takeda Pharma Holdings in June 2009. For more than 20 years, Mr. Walbert held executive positions in general management, corporate strategy, sales, U.S. and international marketing and commercial operations at biopharmaceutical companies such as Abbott Laboratories, G.D. Searle/Pharmacia, Neopharm, Merck & Company and Wyeth. At Abbott, Mr. Walbert served as Divisional Vice President and General Manager, Immunology, leading the global development and launch of HUMIRA, which attained over $8.0 billion in sales in 2011. Mr. Walbert serves on the board of directors of XOMA Ltd., Egalet Corporation, the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO) and the Greater Chicago Arthritis Foundation. Mr. Walbert holds a B.A. in Business and Marketing from Muhlenberg College. We nominated Mr. Walbert to the Board of Directors due to his experience in commercial operations and business strategy and his experience leading a publicly traded biopharmaceutical company.


The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever Raptor Pharmaceutical Corp. makes a similar move, sign up!

Other recent filings from the company include the following:

Raptor Pharmaceutical Corp. director just cashed-in 10,000 options - March 3, 2015
<br/> - March 2, 2015
Raptor Pharmaceutical Corp. director just cashed-in 30,000 options - Feb. 25, 2015
Raptor Pharmaceutical Corp. director just cashed-in 30,000 options - Feb. 19, 2015
Statement of acquisition of beneficial ownership by individuals - Feb. 17, 2015

   Auto Refresh